Evidence map›Paper›PMID 30844048›Full record

Trial reportEuropean heart journal2019

Febuxostat for Cerebral and CaRdiorenovascular Events PrEvEntion StuDy.

Sunao Kojima, Kunihiko Matsui, Shinya Hiramitsu, Ichiro Hisatome, Masako Waki, Kazuaki Uchiyama, Naoto Yokota, Eiichi Tokutake, Yutaka Wakasa, Hideaki Jinnouchi and 9 more

Registry-linked trialOpen access · hybridAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in European heart journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01984749 (A Multicenter, Randomized, Comparative Trial on the Effect of Febuxostat in Preventing Cerebral and Cardiorenovascular Events in Patients With Hyperuricemia), which is not on this map. Cited by 112 papers, 12 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
112citing papers in PubMed, 12 pooled it
17.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01984749 naunknown statusnot on this map

A Multicenter, Randomized, Comparative Trial on the Effect of Febuxostat in Preventing Cerebral and Cardiorenovascular Events in Patients With Hyperuricemia

TypeinterventionalSponsorFreed Study GroupRan2013Enrolled1,000ConditionsHyperuricemiaArmsFebuxostat
3 · Its place in the literature

Who cites it

112 citing papers in PubMed, 12 syntheses or guidelines pooled it, 222 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Febuxostat and renal outcomes: post-hoc analysis of a randomized trial.Hypertension research : official journal of the Japanese Society of Hypertension · 2023
    Trial
  19. Trial
  20. Trial

52 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 11 institutions in 1 country.

Sunao KojimaDepartment of General Internal Medicine 3, Kawasaki Medical School General Center, 2-6-1 Nakasange, Kita-ku, Okayama, Japan.
Kunihiko MatsuiDepartment of Family, Community, and General Medicine, Kumamoto University Hospital, 1-1-1 Honjo, Chuo-ku, Kumamoto, Japan.
Shinya HiramitsuHiramitsu Heart Clinic, 2-35 Shiroshita-cho, Minami-ku, Nagoya, Japan.
Ichiro HisatomeInstitute of Regenerative Medicine and Biofunction, Tottori University Graduate School of Medical Science, 86 Nishi-machi, Yonago, Japan.
Masako WakiShizuoka City Shizuoka Hospital, 10-93 Ote-machi, Aoi-ku, Shizuoka, Japan.
Kazuaki UchiyamaUchiyama Clinic, 1161-1 Shita-machi, Yoshikawa-ku, Joetsu, Japan.
Naoto YokotaYokota Naika, 642-1 Komuta, Hanagashima-cho, Miyazaki, Japan.
Eiichi TokutakeTokutake Iin, 2-28-1 Asahi, Kawaguchi, Japan.
Yutaka WakasaWakasa Medical Clinic, 3-16-25 Sainen, Kanazawa, Japan.
Hideaki JinnouchiJinnouchi Hospital Diabetes Care Center, 6-2-3 Kuhonji, Chuo-ku, Kumamoto, Japan.
Hirokazu KakudaKakuda Iin, Na 15-1, Takamatsu, Kahoku, Japan.
Takahiro HayashiHayashi Medical Clinic, 5-22 Nakamozu-cho, Kita-ku, Sakai, Japan.
Naoki KawaiKawai Naika Clinic, 4-9 Tono-machi, Gifu, Japan.
Hisao MoriYokohama Sotetsu Bldg Clinic of Internal Medicine, 1-11-5 Kitasaiwai, Nishi-ku, Yokohama, Japan.
Masahiro SugawaraSugawara Clinic, 3-9-16 Shakujii-machi, Nerima-ku, Japan.
Yusuke OhyaDepartment of Cardiovascular Medicine, Nephrology and Neurology, University of the Ryukyus School of Medicine, 207 Uehara, Nishihara-cho, Okinawa, Japan.
Kazuo KimuraDivision of Cardiology, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, Yokohama, Japan.
Yoshihiko SaitoDepartment of Cardiovascular Medicine, Nara Medical University, 840 Shijyo-cho, Kashihara, Japan.
Hisao OgawaNational Cerebral and Cardiovascular Center, 5-7-1 Fujishirodai, Suita, Japan.
Hayashi Eye Hospital · JPKanazawa Medical Center · JPKawasaki Medical School · JPKumamoto University Hospital · JPNagoya Heart Center · JPNara Medical University · JPNational Cerebral and Cardiovascular Center · JPShizuoka City Hospital · JPTottori University · JPUniversity of the Ryukyus · JPYokohama City University Medical Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsTo compare the occurrence of cerebral, cardiovascular, and renal events in patients with hyperuricaemia treated with febuxostat and those treated with conventional therapy with lifestyle modification. METHODS AND

resultsThis multicentre, prospective, randomized open-label, blinded endpoint study was done in 141 hospitals in Japan. A total of 1070 patients were included in the intention-to-treat population. Elderly patients with hyperuricaemia (serum uric acid >7.0 to ≤9.0 mg/dL) at risk for cerebral, cardiovascular, or renal disease, defined by the presence of hypertension, Type 2 diabetes, renal disease, or history of cerebral or cardiovascular disease, were randomized to febuxostat and non-febuxostat groups and were observed for 36 months. Cerebral, cardiovascular, and renal events and all deaths were defined as the primary composite event. The serum uric acid level at endpoint (withdrawal or completion of the study) in the febuxostat (n = 537) and non-febuxostat groups (n = 533) was 4.50 ± 1.52 and 6.76 ± 1.45 mg/dL, respectively (P < 0.001). The primary composite event rate was significantly lower in the febuxostat group than in non-febuxostat treatment [hazard ratio (HR) 0.750, 95% confidence interval (CI) 0.592-0.950; P = 0.017] and the most frequent event was renal impairment (febuxostat group: 16.2%, non-febuxostat group: 20.5%; HR 0.745, 95% CI 0.562-0.987; P = 0.041).

conclusionFebuxostat lowers uric acid and delays the progression of renal dysfunction. REGISTRATION: ClinicalTrials.gov (NCT01984749).

Indexed as

Cardiovascular DiseasesHyperuricemiaKidney DiseasesAgedAged, 80 and overDiabetes Mellitus, Type 2FebuxostatFemaleGout SuppressantsHumansMaleProspective StudiesUric AcidFebuxostatGout SuppressantsUric AcidCardiovascular diseaseCerebral diseaseElderly patientFebuxostatHyperuricaemiaRenal disease

Identifiers

PMID30844048
PMCPMC6554652
OpenAlexW2922206684

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.